Insulet (PODD) Receives News Impact Rating of 0.12

Media stories about Insulet (NASDAQ:PODD) have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insulet earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.8053969295982 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Insulet (NASDAQ:PODD) traded down $0.65 during midday trading on Wednesday, hitting $68.69. 235,032 shares of the stock were exchanged, compared to its average volume of 498,349. Insulet has a twelve month low of $36.80 and a twelve month high of $72.99. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. The firm has a market capitalization of $4,030.00, a PE ratio of -137.38 and a beta of 1.58.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The business had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. During the same period in the previous year, the company posted ($0.05) earnings per share. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. equities analysts forecast that Insulet will post -0.43 earnings per share for the current fiscal year.

PODD has been the topic of a number of recent research reports. Barclays initiated coverage on shares of Insulet in a research report on Friday, September 15th. They set an “overweight” rating and a $65.00 price target on the stock. Canaccord Genuity reaffirmed a “hold” rating and set a $50.00 price target on shares of Insulet in a research report on Wednesday, September 27th. Zacks Investment Research cut shares of Insulet from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. Wedbush reaffirmed a “buy” rating and set a $65.00 price target (up from $60.00) on shares of Insulet in a research report on Tuesday, October 10th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $74.00 price target (up from $65.00) on shares of Insulet in a research report on Thursday, October 12th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $61.29.

In other news, Director James C. Mullen bought 2,500 shares of Insulet stock in a transaction dated Monday, November 13th. The shares were acquired at an average cost of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insulet (PODD) Receives News Impact Rating of 0.12” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

What are top analysts saying about Insulet? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insulet and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit